Preferencje help
Widoczny [Schowaj] Abstrakt
Liczba wyników

Znaleziono wyników: 2

Liczba wyników na stronie
first rewind previous Strona / 1 next fast forward last
Wyniki wyszukiwania
help Sortuj według:

help Ogranicz wyniki do:
first rewind previous Strona / 1 next fast forward last
EN
A novel series of 1,3,4-oxadiazole derivatives of mefenamic acid was obtained by reacting hydrazones of mefenamic acid with anhydrous acetic anhydride. The mefenamic hydrazones were obtained by reacting different substituted aldehydes with mefenamic acid hydrazide. All the compounds were characterized by spectral data and elemental analysis. Molecular docking studies of all the compounds were performed against COX-1/COX-2 enzymes. Compound 4 and compound 10 were found to have the highest potential to bind with COX-1 while compound 3, compound 6, and compound 10 were found to have the highest potential to bind with COX-2 enzyme.
2
Content available remote Facile synthesis and anticancer activity of novel dihydropyrimidinone derivatives
EN
The enaminone, (2E)-3-(dimethylamino)-1-(3,4,5-trimethoxyphenyl) prop-2-en-1-one was prepared by refluxing 3,4,5-trimethoxy acetophenone with dimethylformamide dimethylacetal (DMF–DMA) without solvent for 12 h. The dihydropyrimidinone derivatives (1–9) were prepared by reacting enaminone, substituted benzaldehydes and urea in glacial acetic acid. The compounds (1–9) were synthesized in significant yield using one step multicomponent reaction. Structures of all the novel synthesized compounds were characterized and confirmed by various spectroscopic methods. The compounds were evaluated for their anti-cancer activity against HepG2 cancer cell line. Compound 9 displayed significant anti-cancer activity. During the apoptotic assay, it showed a significant increase in necrosis from 1.97% to 12.18% as compared to the control. Mechanism of anti-proliferation was performed by cell cycle distribution assay, which showed a decrease in G2+M from 12.90 to 8.13 as compared to control.
first rewind previous Strona / 1 next fast forward last
JavaScript jest wyłączony w Twojej przeglądarce internetowej. Włącz go, a następnie odśwież stronę, aby móc w pełni z niej korzystać.